Table 3.
Associations between dietary docosahexaenoic acid intake and risk of early age-related macular degeneration progression by types of Age-Related Eye Disease Study intervention*
| Dietary intake | Multivariate-adjusted hazard ratio (95% confidence interval) |
|||
|---|---|---|---|---|
| Placebo |
Antioxidants |
Zinc |
Antioxidants plus zinc |
|
| n = 652 | n = 632 | n = 637 | n = 602 | |
| Docosahexaenoic acid | ||||
| Q2 (26.0–41.9 mg/day) | 0.79 (0.55 to 1.14) | 1.30 (0.91 to 1.85) | 1.59 (1.12 to 2.28) | 1.06 (0.73 to 1.53) |
| Q3 (41.9–64.0 mg/day) | 0.60 (0.40 to 0.89) | 0.92 (0.61 to 1.39) | 1.26 (0.85 to 1.87) | 1.29 (0.88 to 1.89) |
| Q4 (≥64.0 mg/day) | 0.58 (0.37 to 0.92) | 1.23 (0.81 to 1.87) | 1.46 (0.93 to 2.30) | 1.17 (0.74 to 1.85) |
| p Value for trend | 0.01 | 0.63 | 0.22 | 0.29 |
| p Value for interaction | 0.006 | |||
*
Using eyes as the unit in Cox proportional-hazards regression, the multivariate-adjusted hazard ratios (95% CIs) were calculated using the first quartile group of docosahexaenoic acid intake (<26.0 mg/day) as the referent. The p value for interaction evaluated if the association varied by type of Age-Related Eye Disease Study intervention.